Výsledky vyhledávání - "Randall Stoltz"

Safety, Pharmacokinetics, and Pharmacodynamics of Trazpiroben (TAK‐906), a Novel Selective D 2 /D 3 Receptor Antagonist: A Phase 1 Randomized, Placebo‐Controlled Single‐ and Multiple‐Dose Escalation Study in Healthy Participants

Autor: Chunlin Chen, Hongqi Xue, Dan Combs, Roger Lewis Whiting, Borje Darpo, Margaret S. Fletcher, Randall Stoltz

Publikováno v: Clinical Pharmacology in Drug Development. 10:927-939

Gastroparesis is a chronic neuromuscular disorder of the upper gastrointestinal tract in which episodic exacerbation can lead to frequent hospitalizations and severe disability. Dopamine D2 /D3 receptor antagonists have been used to treat patients wi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0216d84dcde90b983edb00f570e90522
https://doi.org/10.1002/cpdd.906

Zobrazit plný text záznamu

Plný text ve formátu HTML

CK-2127107 amplifies skeletal muscle response to nerve activation in humans

Autor: Joyce K. James, Fady I. Malik, Timothy M. Miller, Lisa Meng, Vipin Vijayakumar, Jinsy A. Andrews, Randall Stoltz, Andrew A. Wolff

Publikováno v: Muscle & Nerve. 57:729-734

Introduction Three studies evaluated safety, tolerability, pharmacokinetics, and pharmacodynamics of CK-2127107 (CK-107), a next-generation fast skeletal muscle troponin activator (FSTA), in healthy participants. We tested the hypothesis that CK-107

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3db42ee2d5c4034d308ebc2932e70813
https://doi.org/10.1002/mus.26017

Zobrazit plný text záznamu

A Randomized Phase 1 Dose Escalation Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Trabodenoson in Healthy Adult Volunteers

Autor: Randall Stoltz, Alan M. Laties, Vernon Humbert, Rudolf A. Baumgartner, Cadmus C Rich, Mcvicar William K, Chaim Brickman

Publikováno v: Journal of Ocular Pharmacology and Therapeutics

Purpose: To investigate the safety, tolerability, and pharmacokinetics of trabodenoson, a highly selective adenosine mimetic targeting the adenosine A1 receptor. Methods: In Part 1, 60 healthy adult volunteers were randomized to 14 days of twice-dail

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::57afd9b6611e390b6e010045e04cfa27
https://doi.org/10.1089/jop.2015.0147

Zobrazit plný text záznamu

The Absolute Bioavailability and Effect of Food on the Pharmacokinetics of Odanacatib: A Stable-Label i.v./Oral Study in Healthy Postmenopausal Women

Autor: Rose Witter, David Hreniuk, Filippos Kesisoglou, Roy Helmy, Stefan Zajic, Julie A. Stone, Darrick Joss, S. Aubrey Stoch, Don Gauthier, Stefaan Rossenu, Tong Ni, Fang Liu, Li Sun, Randall Stoltz, Jacqueline B. McCrea

Publikováno v: Drug Metabolism and Disposition. 44:1450-1458

A stable-label i.v./oral study design was conducted to investigate the pharmacokinetics (PK) of odanacatib. Healthy, postmenopausal women received oral doses of unlabeled odanacatib administered simultaneously with a reference of 1 mg i.v. stable (13

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e2906899c0c7e5d982b75e0cfa706575
https://doi.org/10.1124/dmd.116.069906

Zobrazit plný text záznamu

Effect of ceralifimod (ONO-4641) on lymphocytes and cardiac function: Randomized, double-blind, placebo-controlled trial with an open-label fingolimod arm

Autor: Tanya Fischer, Randall Stoltz, Peter Wolna, Borje Darpo, Meijian Zhou, Sonja Krösser, Ursula Boschert

Publikováno v: The Journal of Clinical Pharmacology. 55:1051-1060

This randomized, double-blind, placebo-controlled, 6-arm, parallel-design study investigated cardiac and hematological pharmacodynamic effects of ceralifimod (ONO-4641), a selective sphingosine-1-phosphate (S1P) receptor modulator, over a broad dose

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a676e0b805db9904efef1708d3c7b218
https://doi.org/10.1002/jcph.513

Zobrazit plný text záznamu

Effect of Ponesimod, a Selective S1P1Receptor Modulator, on the QT Interval in Healthy Individuals

Autor: Jasper Dingemanse, Randall Stoltz, Borje Darpo, Meijian Zhou, Patrick Brossard, Matthias Hoch

Publikováno v: Basic & Clinical Pharmacology & Toxicology. 116:429-437

Ponesimod is an orally active selective sphingosine-1-phosphate receptor 1 modulator under investigation for the treatment of multiple sclerosis. This was a single-centre, double-blind, randomized, placebo- and positive-controlled parallel-group stud

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c49bc0e992a7c1270c08867e61d9bb95
https://doi.org/10.1111/bcpt.12336

Zobrazit plný text záznamu

Safety, tolerability, and pharmacokinetic evaluation of single- and multiple-ascending doses of a novel kappa opioid receptor antagonist LY2456302 and drug interaction with ethanol in healthy subjects

Autor: Jennifer Witcher, Linda M. Rorick-Kehn, Conrad J. Wong, Gemma L. Dickinson, Celedon Gonzales, Randall Stoltz, Robert Bell, Stephen L. Lowe, Sitra Tauscher-Wisniewski, MaryAnn Weller, Jane Royalty

Publikováno v: The Journal of Clinical Pharmacology. 54:968-978

Accumulating evidence indicates that selective antagonism of kappa opioid receptors may provide therapeutic benefit in the treatment of major depressive disorder, anxiety disorders, and substance use disorders. LY2456302 is a high-affinity, selective

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a9ca0c913986733965edb67a81dab579
https://doi.org/10.1002/jcph.286

Zobrazit plný text záznamu

Multiple-Dose Pharmacokinetics and Pharmacodynamics of Sergliflozin Etabonate, a Novel Inhibitor of Glucose Reabsorption, in Healthy Overweight and Obese Subjects: A Randomized Double-Blind Study

Autor: Anita Kapur, Robert L. Dobbins, Robin L. O'Connor-Semmes, Derek J. Nunez, Randall Stoltz, Sharon C. Murray, Elizabeth K. Hussey, Debbi Layko, Nancy L. Stockman

Publikováno v: The Journal of Clinical Pharmacology. 50:636-646

Sergliflozin, the active entity of sergliflozin etabonate, is a selective inhibitor of the sodium-dependent glucose cotransporter-2 in the renal tubule. The pharmacokinetics and pharmacodynamics of sergliflozin were examined during administration of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d9d6d57a92bb1f293f4ae30984a039a
https://doi.org/10.1177/0091270009352185

Zobrazit plný text záznamu

A Thorough QTc Study to Assess the Effect of Sitagliptin, a DPP4 Inhibitor, on Ventricular Repolarization in Healthy Subjects

Autor: Arthur J. Bergman, David Hreniuk, Maria Gutierrez, Lisa Hickey, Daniel M. Bloomfield, Kalyan Ghosh, Gary A. Herman, Rajesh Krishna, Randall Stoltz, Jutta Miller, John A. Wagner, Keith Gottesdiener

Publikováno v: The Journal of Clinical Pharmacology. 49:937-946

A randomized, double-blind, placebo-controlled, 4-period crossover study was performed with a single oral dose of sitagliptin (100 mg, 800 mg), moxifloxacin (400 mg), and placebo in order to provide a rigorous assessment of the effect of sitagliptin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d1b9f7f1d0ddfefc9fd977ec2442361
https://doi.org/10.1177/0091270009337511

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání